

CHMP Chair
European Medicines Agency
Domenico Scarlattilaan 6
1083 HS Amsterdam
The Netherlands

Subject: Withdrawal of H0005845 (company name: CVnCoV, INN: Zorecimeran, COVID-19 mRNA vaccine candidate)

Dear CHMP Chair,

I would like to inform you that, at this point of time, CureVac AG has taken the decision to withdraw the application for Marketing Authorisation of H0005845 (company name: CVnCoV, INN: Zorecimeran, COVID-19 mRNA vaccine candidate), which was intended to be used for active immunisation to prevent COVID-19 caused by SARS-CoV-2.

This withdrawal is based on the following reason:

CureVac AG made the strategic decision to focus its COVID-19 vaccine development on a second generation vaccine program.

Ongoing clinical trials with CVnCoV will be continued and finalized as planned including follow-up.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

Yours sincerely,

Executive Director Regulatory Affairs

CureVac AG

Friedrich-Miescher-Strasse 15
72076 Tübingen, Germany
T +49 7071 9883-0
F +49 7071 9883-1101
info@curevac.com
www.curevac.com

Management Board

Dr. Franz-Werner Haas, Dr. Mariola Fotin-Mleczek,
Dr. Malte Greune, Pierre Kemula,
Antony Blanc, Ph.D., Igor Splawski, Ph.D.,
Dr. Klaus Edvardsen
Chairman of the Supervisory Board
Jean Stéphenne

Registered Seat

Local Court Stuttgart
HRB 754041
Tax No.
Tax No.: 86111/81703
VAT-ID: DE 221 393 632

Bank Details

Kreissparkasse Tübingen
Bank Code: 641 500 20
Account: 122 885
IBAN: DE68 6415 0020 0000 1228 85
SWIFT-BIC: SOLA DE S1 TUB